Funding from Charity for New Treatments to Silence Tinnitus
News Feb 06, 2015
To mark Tinnitus Awareness Week, UK charity Action on Hearing Loss has announced a major investment to fund a new study at Newcastle University, which aims to accelerate the development of future tinnitus treatments.
Six million people in the UK are affected by tinnitus every day - ranging from a light buzzing to a constant roar in the ears and head - with 600,000 seriously affected by the condition, which can have a detrimental effect on quality of life including bouts of anxiety, difficulties socializing and problems sleeping or being able to concentrate at work.
The three year, £300,000 project will be led by Dr Mark Cunningham at Newcastle University and will involve researchers at Leicester University and the biotechnology company Autifony Therapeutics Ltd, who are currently conducting a clinical trial of a drug for tinnitus.
The pioneering research aims to bridge the gap between promising laboratory research discoveries and testing new medicines in tinnitus patients.
Lead researcher, Dr Mark Cunningham (pictured) said: "The focus of this project is to see if we can use electrical waves in one of the hearing centres of the brain to measure tinnitus both to discover if the therapy developed by Autifony is working and how it is having its effect. The use of an animal model of tinnitus will allow us to investigate brain wave activity in the hearing centres and develop a biological measure which can be used on patients in the clinic as well as future research."
Dr Ralph Holme, Head of Biomedical Research at charity Action on Hearing Loss, said: "Tinnitus is a debilitating condition for which there is no cure, but real progress is being made towards understanding the mechanisms behind the condition, giving us hope that effective treatments can be found.
"Currently the search for new treatments is being slowed down because it is very hard to know if the effects of potential new treatments seen in animal studies are relevant to tinnitus in humans. Our new project has the potential to overcome this barrier, speeding up the development of urgently needed treatments."
Action on Hearing Loss (formerly RNID) runs the world’s largest donor-supported hearing research programme, dedicated to funding research into better treatments and cures for hearing loss and tinnitus.
Tinnitus Awareness Week is taking place from 2 - 8 February.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018